GlassScriptPhysician profile
Christopher S Chow
NPI 1386644136
$6,046.59
in general payments reported to CMS, 2019-2025
36 companies · $911 in 2025
The $911 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $631 · 2021: $577 · 2022: $804 · 2023: $1,105 · 2024: $1,385 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.35 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.72 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.93 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Lilly USA, LLC | $476.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $445.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $403.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $402.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $351.10 | 2020-2025 | Veozah |
| Novo Nordisk INC | $325.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $255.71 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.84 | 2019-2025 | Xifaxan |
| Amgen INC. | $165.56 | 2019-2024 | Krystexxa |
| Allergan, INC. | $143.62 | 2019-2020 | |
| Amarin Pharma, INC. | $129.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.87 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $104.81 | 2022-2025 | Eliquis |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.